Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 591
5
Diseases
4
Unique genes
0.405
Avg. similarity score
Brain stem astrocytic neoplasm
Most-connected disease (4 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Brain stem astrocytic neoplasm
Optic tract astrocytoma
Retina neoplasm
Retinitis pigmentosa 86
Fibrodysplasia ossificans progressiva
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Brain stem astrocytic neoplasm | 4 | 4 | 4 |
| Optic tract astrocytoma | 3 | 3 | 2 |
| Retina neoplasm | 3 | 3 | 2 |
| Retinitis pigmentosa 86 | 3 | 3 | 1 |
| Fibrodysplasia ossificans progressiva | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| KIAA1549 | 4 / 5 | Brain stem astrocytic neoplasm, Optic tract astrocytoma, Retina neoplasm, Retinitis pigmentosa 86 |
| BRAF | 3 / 5 | Brain stem astrocytic neoplasm, Optic tract astrocytoma, Retina neoplasm |
| ACVR1 | 2 / 5 | Brain stem astrocytic neoplasm, Fibrodysplasia ossificans progressiva |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Thyroid cancer | KEGG | 2 / 37 | 162× | 5.52e-5 | 1.18e-3 ✓ sig. |
| Bladder cancer | KEGG | 2 / 41 | 146× | 6.79e-5 | 1.39e-3 ✓ sig. |
| Endometrial cancer | KEGG | 2 / 59 | 102× | 1.41e-4 | 2.50e-3 ✓ sig. |
| Signaling by BRAF and RAF fusions | Reactome | 2 / 67 | 89.6× | 1.83e-4 | 3.06e-3 ✓ sig. |
| Melanoma | KEGG | 2 / 73 | 82.3× | 2.17e-4 | 3.50e-3 ✓ sig. |
| Non-small cell lung cancer | KEGG | 2 / 73 | 82.3× | 2.17e-4 | 3.50e-3 ✓ sig. |
| Glioma | KEGG | 2 / 76 | 79.0× | 2.35e-4 | 3.73e-3 ✓ sig. |
| Pancreatic cancer | KEGG | 2 / 77 | 78.0× | 2.41e-4 | 3.80e-3 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 2 / 77 | 78.0× | 2.41e-4 | 3.80e-3 ✓ sig. |
| Colorectal cancer | KEGG | 2 / 87 | 69.0× | 3.08e-4 | 4.60e-3 ✓ sig. |
| Prostate cancer | KEGG | 2 / 98 | 61.3× | 3.91e-4 | 5.53e-3 ✓ sig. |
| Endocrine resistance | KEGG | 2 / 99 | 60.7× | 3.99e-4 | 5.61e-3 ✓ sig. |
| Neurotrophin signaling pathway | KEGG | 2 / 120 | 50.0× | 5.86e-4 | 7.55e-3 ✓ sig. |
| Regulation of TP53 Expression | Reactome | 1 / 2 | 1,501× | 6.66e-4 | 8.31e-3 ✓ sig. |
| Fluid shear stress and atherosclerosis | KEGG | 2 / 141 | 42.6× | 8.09e-4 | 9.63e-3 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| gastrulation | GO:0007369 | 2 / 38 | 246× | 2.41e-5 | 1.06e-3 ✓ sig. |
| T cell differentiation in thymus | GO:0033077 | 2 / 41 | 228× | 2.81e-5 | 1.19e-3 ✓ sig. |
| cellular response to xenobiotic stimulus | GO:0071466 | 2 / 65 | 144× | 7.12e-5 | 2.40e-3 ✓ sig. |
| transforming growth factor beta receptor signaling pathway | GO:0007179 | 2 / 112 | 83.4× | 2.12e-4 | 5.30e-3 ✓ sig. |
| negative regulation of helicase activity | GO:0051097 | 1 / 1 | 4,672× | 2.14e-4 | 5.31e-3 ✓ sig. |
| regulation of intrinsic apoptotic signaling pathway by p53 class mediator | GO:1902253 | 1 / 1 | 4,672× | 2.14e-4 | 5.31e-3 ✓ sig. |
| negative regulation of G1 to G0 transition | GO:1903451 | 1 / 1 | 4,672× | 2.14e-4 | 5.31e-3 ✓ sig. |
| endocardial cushion cell fate commitment | GO:0061445 | 1 / 1 | 4,672× | 2.14e-4 | 5.31e-3 ✓ sig. |
| regulation of thymocyte apoptotic process | GO:0070243 | 1 / 2 | 2,336× | 4.28e-4 | 8.53e-3 ✓ sig. |
| oligodendrocyte apoptotic process | GO:0097252 | 1 / 2 | 2,336× | 4.28e-4 | 8.53e-3 ✓ sig. |
| negative regulation of glucose catabolic process to lactate via pyruvate | GO:1904024 | 1 / 2 | 2,336× | 4.28e-4 | 8.53e-3 ✓ sig. |
| negative regulation of pentose-phosphate shunt | GO:1905856 | 1 / 2 | 2,336× | 4.28e-4 | 8.53e-3 ✓ sig. |
| positive regulation of determination of dorsal identity | GO:2000017 | 1 / 2 | 2,336× | 4.28e-4 | 8.53e-3 ✓ sig. |
| intrinsic apoptotic signaling pathway in response to hypoxia | GO:1990144 | 1 / 3 | 1,557× | 6.42e-4 | 1.11e-2 ✓ sig. |
| positive T cell selection | GO:0043368 | 1 / 3 | 1,557× | 6.42e-4 | 1.11e-2 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Optic tract astrocytoma | Retinitis pigmentosa 86 | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Optic tract astrocytoma | Retina neoplasm | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Retina neoplasm | Retinitis pigmentosa 86 | 0.500 | 1 | 6.46e-5 | 1.98e-4 ✓ sig. |
| Brain stem astrocytic neoplasm | Fibrodysplasia ossificans progressiva | 0.333 | 1 | 1.29e-4 | 3.27e-4 ✓ sig. |
| Brain stem astrocytic neoplasm | Retinitis pigmentosa 86 | 0.333 | 1 | 1.29e-4 | 3.27e-4 ✓ sig. |
| Brain stem astrocytic neoplasm | Optic tract astrocytoma | 0.333 | 1 | 1.29e-4 | 3.27e-4 ✓ sig. |
| Brain stem astrocytic neoplasm | Retina neoplasm | 0.333 | 1 | 1.29e-4 | 3.27e-4 ✓ sig. |